The Patent Finder

Escape Therapeutics, Inc.

14 patents currently held · Updated Nov 16, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Mar 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 3, 2027
    The maintenance fee for Method of cell transplantation into a human recipient (US 9,173,904) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 1 fee due Sep 3, 2027
    The maintenance fee for Mesenchymal stem cells with enhanced immunosuppressive capability (US 10,576,105) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
  • 1 fee due Oct 26, 2027
    The maintenance fee for Peptide tyrosinase inhibitors and uses thereof (US 9,320,698) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,173,904Method of cell transplantation into a human recipient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,647,871Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,822,215Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,347,045Differentiation of mesenchymal stem cells into fibroblasts
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,382,514Compositions comprising mesenchymal stem cell-derived fibroblasts
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,911,723Hybrid hydrogel scaffold compositions and methods of use
In force (reinstated)
 · From the USPTO record
In force (reinstated)From the USPTO record
US 9,320,698Peptide tyrosinase inhibitors and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,053,670Enhanced differentiation of mesenchymal stem cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,554,746System for evaluating skin treatment
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,567,368Peptide tyrosinase activators
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 3 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 4 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited